KIAA1429 in non-small cell lung cancer: bridging m6A epigenetics to therapeutic innovation
Clicks: 1
ID: 310292
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #477 of 490 articles by views in Frontiers in surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 490 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
As a pivotal component of the m6A methyltransferase complex, KIAA1429 plays a critical regulatory role in the pathogenesis of non-small cell lung cancer (NSCLC), driving tumorigenesis, metastasis, and therapeutic resistance through epigenetic mechanisms. Clinically, KIAA1429 overexpression correlates with aggressive disease progression and poor patient prognosis to conventional therapies. This review comprehensively examines the dysregulated expression patterns and functions of KIAA1429 in NSCLC, elucidating its m6A-dependent modulation of key downstream effectors (Such as the HOXA1, DAPK3, and BTG2) that orchestrate malignant transformation. We highlight the emerging potential of KIAA1429 as a novel molecular target for precision therapy in NSCLC.
| Reference Key |
imported_1768925843_696faa939efd2
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Li, Dan |
| Journal | Frontiers in surgery |
| Year | 2025 |
| DOI |
10.3389/fsurg.2025.1643120
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.